Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Get Free Report) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.00 and traded as high as $7.60. Cryo-Cell International shares last traded at $7.40, with a volume of 28,467 shares changing hands.
Cryo-Cell International Stock Performance
The firm has a market cap of $59.72 million, a PE ratio of -6.99 and a beta of 0.49.
Cryo-Cell International (NYSEAMERICAN:CCEL - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.02 by $0.11. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%. The company had revenue of $8.07 million during the quarter.
Cryo-Cell International Dividend Announcement
The company also recently announced a -- dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.25 dividend. The ex-dividend date of this dividend was Friday, November 15th. Cryo-Cell International's payout ratio is -94.34%.
Institutional Investors Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Geode Capital Management LLC lifted its stake in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Free Report) by 68.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,860 shares of the company's stock after buying an additional 16,203 shares during the period. Geode Capital Management LLC owned approximately 0.49% of Cryo-Cell International worth $254,000 as of its most recent filing with the Securities and Exchange Commission. 10.44% of the stock is currently owned by hedge funds and other institutional investors.
Cryo-Cell International Company Profile
(
Get Free Report)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.
See Also
Before you consider Cryo-Cell International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryo-Cell International wasn't on the list.
While Cryo-Cell International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
